Pimavanserin
Back to searchMolecule Structure
Scientific Name
Pimavanserin
Description of the Drug
Pimavanserin is a second generation atypical antipsychotic used for the treatment of hallucinations and delusions caused by Parkinson’s Disease.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB05316
http://www.drugbank.ca/drugs/DB05316
Brand Name(s)
Not Available
Company Owner(s)
Acadia Pharmaceuticals Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Serotonin 2a (5-HT2a) receptor | SINGLE PROTEIN | INVERSE AGONIST | CHEMBL224 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL675165 | ||
| Human Metabolome Database | HMDB0256551 | ||
| DrugBank | DB05316 | ||
| PubChem: Thomson Pharma | 15056570 | ||
| PubChem | 10071196 | ||
| LINCS | LSM-45960 | ||
| BindingDB | 139370 | ||
| DrugCentral | 5142 | ||
| ChemicalBook | CB8966229 | ||
| Guide to Pharmacology | 8423 | ||
| rxnorm | PIMAVANSERIN TARTRATE | PIMAVANSERIN | NUPLAZID |
| ChEBI | 133017 | ||
| ZINC | ZINC000016159083 |
